Abstract:Objective:To explore the genetic mutation, clinical characteristics, diagnosis and treatment of patients with hereditary coagulation factor FⅪ deficiency.Methods:On August 10 and October 30, 2020, two patients with hereditary FⅪ deficiency who were admitted at Department of Hematology, West China Hospital of Sichuan University were selected as research subjects. Patients 1 and 2 were numbered according to visiting time. Diagnosis was made according to coagulation function test and results of gene sequencing F11 gene.Clinical observation or symptomatic treatment were performed according to clinical bleeding symptom and severity. Novel mutations were confirmed by retrieving Human Gene Mutation database (HGMD), Single Nucleotide Polymorphism Database (dbSNP) and PubMed database. Pathogenicity of the novel missense mutation was predicted by computational software of Mutation Taster, Polyphen-2, and PROVEAN. Follow-up of patients was conducted until February 28, 2021. Clinical manifestations and process of diagnosis and treatment of two patients were analyzed retrospectively. China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, PubMed database were searched for the same and similar case reports as F11 genetic mutation in this study.Retrieval time was from database inception to February 28, 2021. Types of genetic mutations and clinical manifestations related to patients in this study were summarized.This study meeted the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Informed consent of patients was obtained from pateints. Results:① Results of medical history: patient 1, a 24 years old man, was admitted due to " hematoma after soft tissue trauma in left thigh and preoperative examination revealed coagulation dysfunction" and did not complain of significant discomfort.Patient 2, a 32 years old woman, was admitted due to " pre-pregnancy physical examination found prolonged activated partial thromboplastin time (APTT)" and complained of occasional ecchymosis.② Results of related laboratory examination: APTT, prothrombin time (PT) and FⅪ activity (FⅪ∶C) of patient 1 were 97.9 s, 11.9 s and 0.6%, while patient 2 were 95.4 s, 12.5 s, and 1.2%, respectively. ③ Results of DNA sequencing: patient 1 had a compound heterozygous missense mutation of F11 gene at c. 149G>T(p.Cys50Phe) and c. 1204C>T (p.Gln402Ter), while patient 2 had a homozygous deletion of F11 gene at c. 1058delA (p.Asn353ThrfsTer18). ④ F11 gene missense mutation at c. 149G>T(p.Cys50Phe) and deletion c. 1058delA(p.Asn353ThrfsTer18) were two novel mutations and both were pathogenic.⑤Results of treatment and follow-up: two patients received clinical observation. At end of follow-up, general condition of the patients was good. ⑥ Results of literatures review: among 10 patients reported in 6 relevant literatures, there were 1, 3, 6 patients caused by heterozygous nonsense mutation of c. 1204C>T(p.Gln402Ter), nonsense mutation of c. 1202C>T(p.Trp401Ter) adjacent to c. 1204C>T (p.Gln402Ter) and missense mutations near the position of c. 149G>T(p.Cys50Phe), respectively. Conclusions:Two novel mutations of hereditary FⅪ deficiency namely a missense mutation at c. 149G>T(p.Cys50Phe) and a deletion at c. 1058delA(p.Asn353ThrfsTer18) of F11 gene were reported in this study. Both of the two mutations related to decrease of FⅪ∶C.

Establishment the clot waveform analysis reference intervals for four coagulation parameters and clinical application study

Establishment of Normal Reference Intervals for Coagulation Test Indicators in Children

Biological and analytical variations of 16 parameters related to coagulation screening tests and the activity of coagulation factors.

Biological and Analytical Variations of 16 Parameters Related to Coagulation Screening Tests and the Activity of Coagulation Factors

Genetic analysis of patients with hereditary coagulation factor Ⅺ deficiency and literatures review

Clot Waveform Analysis for Monitoring Hemostasis

Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability – A Review

Building And Clinical Use Of Activated Plasma Clotting Time Test And The Value Of Apct On Predicting The Bleeding Due To Leukemia Chemotherapy-Induced Thrombocytopenia

The Role of Clot Waveform Analysis and Related Parameters in the Diagnosis and Treatment of Hemophilia A

Establishop of Reference Ranges for PT、aPTT、Fbg and TT by STA-campact Automated Blood Coagulation Analayzer

Enhanced Hypercoagulability Using Clot Waveform Analysis in Patients with Acute Myocardial Infarction and Acute Cerebral Infarction

A multicenter reference interval study of thromboelastography in the Chinese adult population

Activated partial thromboplastin time-based clot waveform analysis: a potential for application in acute myocardial infarction and its complications

Performance Evaluation of Clinical Detection of Coagulation Factors, Protein S, Protein C, Anti-thrombin Ⅲ, and von Willebrand Factor Antigen

A single-center study of reference intervals for TAT, PIC, TM and t-PAIC in healthy older Chinese adults

Harmonization of the Results of Automated Coagulation Tests with Different Analyzers

Clinical Analysis of Hereditary Coagulation Factorⅴdeficiency

Quantification of the contribution of individual coagulation factors to haemostasis using a microchip flow chamber system and reconstituted blood from deficient plasma

Effects of Individual-Related Variables on Routine Coagulation Parameters in Apparent Healthy

Reference intervals for coagulation parameters in non-pregnant and pregnant women

Reference intervals for coagulation tests in adults with different ABO blood types